loading
Sonoma Pharmaceuticals Inc. stock is currently priced at $0.1566, with a 24-hour trading volume of 126.63K. It has seen a -6.84% decreased in the last 24 hours and a +12.66% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $0.1691 pivot point. If it approaches the $0.1523 support level, significant changes may occur.

Sonoma Pharmaceuticals Inc. Stock (SNOA) Financials Data

Sonoma Pharmaceuticals Inc. (SNOA) Revenue 2024

SNOA reported a revenue (TTM) of $12.31 million for the quarter ending December 31, 2023, a -1.96% decline year-over-year.
loading

Sonoma Pharmaceuticals Inc. (SNOA) Net Income 2024

SNOA net income (TTM) was -$5.08 million for the quarter ending December 31, 2023, a +25.21% increase year-over-year.
loading

Sonoma Pharmaceuticals Inc. (SNOA) Cash Flow 2024

SNOA recorded a free cash flow (TTM) of -$5.20 million for the quarter ending December 31, 2023, a +0.88% increase year-over-year.
loading

Sonoma Pharmaceuticals Inc. (SNOA) Earnings per Share 2024

SNOA earnings per share (TTM) was -$0.94 for the quarter ending December 31, 2023, a +59.31% growth year-over-year.
loading
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a HOCl-based topical prescription product indicated to promote efficient healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens, as well as antibiotic-resistant strains that slow the natural healing of wounds. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Microdacyn60 oral care solution for the treatment of mouth and throat infections; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; Pediacyn atopic dermatitis hydrogel; Ocucyn eyelid and eyelash cleanser; Gramaderm for the treatment of topical mild to moderate acne; Nanocyn, a hospital-grade disinfectant; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.
$13.57
price up icon 1.19%
$72.00
price down icon 6.12%
$55.80
price down icon 0.29%
drug_manufacturers_specialty_generic RDY
$70.91
price down icon 0.56%
$11.12
price up icon 0.18%
$132.54
price down icon 0.52%
Cap:     |  Volume (24h):